Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
01 2022
Historique:
received: 22 06 2021
revised: 15 09 2021
accepted: 06 10 2021
pubmed: 23 10 2021
medline: 8 2 2022
entrez: 22 10 2021
Statut: ppublish

Résumé

The current COVID-19 pandemic illustrates the importance of obtaining reliable methods for the rapid detection of SARS-CoV-2. A highly specific and sensitive diagnostic test able to differentiate the SARS-CoV-2 virus from common human coronaviruses is therefore needed. Coronavirus nucleoprotein (N) localizes to the cytoplasm and the nucleolus and is required for viral RNA synthesis. N is the most abundant coronavirus protein, so it is of utmost importance to develop specific antibodies for its detection. In this study, we developed a sandwich immunoassay to recognize the SARS-CoV-2 N protein. We immunized one alpaca with recombinant SARS-CoV-2 N and constructed a large single variable domain on heavy chain (VHH) antibody library. After phage display selection, seven VHHs recognizing the full N protein were identified by ELISA. These VHHs did not recognize the nucleoproteins of the four common human coronaviruses. Hydrogen Deuterium eXchange-Mass Spectrometry (HDX-MS) analysis also showed that these VHHs mainly targeted conformational epitopes in either the C-terminal or the N-terminal domains. All VHHs were able to recognize SARS-CoV-2 in infected cells or on infected hamster tissues. Moreover, the VHHs could detect the SARS variants B.1.17/alpha, B.1.351/beta, and P1/gamma. We propose that this sandwich immunoassay could be applied to specifically detect the SARS-CoV-2 N in human nasal swabs.

Identifiants

pubmed: 34678315
pii: S0021-9258(21)01093-0
doi: 10.1016/j.jbc.2021.101290
pmc: PMC8526496
pii:
doi:

Substances chimiques

Nucleocapsid Proteins 0
Single-Domain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101290

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Marion Gransagne (M)

Département de Santé Globale, Institut Pasteur, Paris, France.

Gabriel Aymé (G)

Plateforme d'Ingénierie des Anticorps, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Sébastien Brier (S)

Plateforme technologique de RMN biologique, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Gaëlle Chauveau-Le Friec (G)

Plateforme d'Ingénierie des Anticorps, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Véronique Meriaux (V)

Plateforme d'Ingénierie des Anticorps, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Mireille Nowakowski (M)

Plateforme Technologique Production et Purification de Protéines Recombinantes, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

François Dejardin (F)

Plateforme Technologique Production et Purification de Protéines Recombinantes, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Sylvain Levallois (S)

Biology of Infection Unit, Institut Pasteur, Inserm U1117, Paris, France.

Guilherme Dias de Melo (G)

Lyssavirus Epidemiology and Neuropathology Unit, Institut Pasteur, Paris, France.

Flora Donati (F)

Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris, Institut Pasteur, Paris, France; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.

Matthieu Prot (M)

Evolutionary Genomics of RNA Viruses, Institut Pasteur, Paris, France.

Sébastien Brûlé (S)

Plateforme de Biophysique Moléculaire, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Bertrand Raynal (B)

Plateforme de Biophysique Moléculaire, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Jacques Bellalou (J)

Plateforme Technologique Production et Purification de Protéines Recombinantes, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Pedro Goncalves (P)

Unité d'Immunité Innée, Institut Pasteur, Paris, France; INSERM U1223, Paris, France.

Xavier Montagutelli (X)

Mouse Genetics Laboratory, Institut Pasteur, Paris, France.

James P Di Santo (JP)

Unité d'Immunité Innée, Institut Pasteur, Paris, France; INSERM U1223, Paris, France.

Françoise Lazarini (F)

Perception and Memory Unit, Institut Pasteur, CNRS UMR 3571, Paris, France.

Patrick England (P)

Plateforme de Biophysique Moléculaire, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Stéphane Petres (S)

Plateforme Technologique Production et Purification de Protéines Recombinantes, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France.

Nicolas Escriou (N)

Département de Santé Globale, Institut Pasteur, Paris, France.

Pierre Lafaye (P)

Plateforme d'Ingénierie des Anticorps, C2RT, Institut Pasteur, CNRS UMR 3528, Paris, France. Electronic address: plafaye@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH